Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Allogenetics Raises €3.8 Million Pre-Series A to Advance Novel Ex Vivo Gene Therapy Approach to Improve Organ Transplantation OutcomesAllogenetics Raises €3.8 Million Pre-Series A to Advance Novel Ex Vivo Gene Therapy Approach to Improve Organ Transplantation Outcomes
- 2026 Obstructive Sleep Apnea (OSA) Competitive Landscape and Clinical Trial Analysis - 18+ Companies Advance New OSA TherapiesLate-stage pipelines and regulatory momentum create licensing and partnership potential
- Global DNA and Gene Cloning Services Market to Reach $15.6 Billion by 2034 as Therapeutic Pipelines Expand and Organizations Adopt Outsourced, Technology-Enabled Molecular Biology ServicesThe "DNA and Gene Cloning Services - Market Insights, Competitive Landscape, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's offering.
- Evotec SEJust - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical StudiesFirst-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies Program Supports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes...
- Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application DeadlineCapricor Therapeutics (CAPR) Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
- InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in ChinaICP-B381 is InnoCare’s first bispecific ADC to enter the clinic and the third ADC to enter clinical trials.
- UNCY SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors - Contact Kirby McInerney LLP by November 2, 2026Kirby McInerney LLP reminds investors who purchased Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities to contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests in the securities fraud class action lawsuit at no cost.
- REGN 6-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Investors Alerted to September 14, 2026 Lead Plaintiff Deadline in Class Action LawsuitInvestors who lost money in REGN after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
- XORTX Therapeutics Inc.XORTX Re-Engages Investor Relations ProgramXORTX Therapeutics Inc. ("XORTX" or the “Company”) announces that, following completion of its previously announced voluntary delisting from the TSX Venture Exchange, XORTX has re-engaged IR Agency LLC pursuant to a consulting agreement providing for investor relations and marketing services on substantially the same terms previously disclosed by the Company in its news releases dated May 19, 2026 and August 28, 2026.
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that on September 4, 2026, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 4,200 shares of its common stock to two new employees. These stock options are subject to the terms of the Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan (the “Inducement Plan”). The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to their entering into employment with Seres pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by Seres’ board of directors in December 2022. The stock options have an exercise price of $5.72 per share. Each option will vest as to 25% of the total number of shares subject to the option on the first anniversary of the individual’s date of hire and as to 6.25% of the total number of shares subject to the option upon completion of each three full months of service to the Company thereafter.
- Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. and Encourages Investors to Contact the FirmBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
- Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual MeetingInhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q filed August 14, 2026, and encouraged stockholders and other interested parties to review the filing for a more complete discussion of the Company’s progress.